Trials / Withdrawn
WithdrawnNCT00892021
Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder
An Ascending Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Subjects With Schizophrenia or Schizoaffective Disorder
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety of multiple doses of NSA-789 in subjects with schizophrenia or schizoaffective disorder. This study will also assess how NSA-789 is absorbed and eliminated, and its effect, if any, on the brain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NSA-789 | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2009-05-04
- Last updated
- 2021-08-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00892021. Inclusion in this directory is not an endorsement.